Figure 7: Pharmacokinetic-pharmacodynamic simulations with WinNonlin® software to predict INR response in patients with therapy range of 2-3 (n=114), resulting from the combination of our derived pharmacogenetic-based model (equation 1) for initiation dose regimen, and formulas by Avery et al. [37] to predict the individualized initial dose regimen for patients commencing anticoagulation therapy (patients WPRA001-WPRA171 excluding patients with INR target range of 2.5-3.5).